查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093371

癌症切片檢查市場：全球預測，2026-2032年

Cancer Biopsy Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症切片檢查市場將成長至 613.5 億美元，複合年成長率為 8.44%。

主要市場統計數據
基準年 2025 347.7億美元
預計年份：2026年 376.3億美元
預測年份 2032 613.5億美元
複合年成長率 (%) 8.44%

切片檢查仍然是腫瘤學診斷、分期、治療選擇和疾病後續觀察的基礎。該領域涵蓋組織切片檢查、細針穿刺活體組織切片、粗針穿刺切片檢查、手術切片檢查、影像引導切片檢查、液態生物檢體、循環腫瘤DNA檢測以及分子病理學工作流程。全球癌症負擔、早期篩檢工作以及精準腫瘤學的擴展推動了活體組織切片需求的成長。在精準腫瘤學中，基於生物標記的治療決策越來越依賴可靠的腫瘤取樣和基因組特徵分析。已證實的臨床實踐模式表明，切片檢查結果可指導腫瘤分類、受體檢測、突變譜分析、免疫組織化學、次世代定序以及標靶治療治療和免疫治療的合格指南。同時，臨床醫生優先考慮微創手術、快速獲得結果、檢體適用性、病人安全以及病理科、放射科、腫瘤科和實驗室資訊系統之間的協作。因此，癌症切片檢查的經營團隊前景正在從單純的診斷轉變為持續的、循證的癌症管理模式，該模式整合了組織形態學、分子數據、影像學和縱向監測。

一項革命性的變革，將徹底改變癌症切片檢查。

隨著腫瘤學從單一診斷轉向動態疾病分析，癌症切片檢查領域正在經歷結構性變革。影像導引切片檢查提高了肺癌、乳癌、肝癌、前列腺癌和深部組織腫瘤病灶的標靶化，而內視鏡和機器人輔助活體組織切片則拓展了對解剖結構複雜部位的活體組織切片途徑。分子檢測也在改變檢體要求，預分析質量、固定方案、腫瘤細胞密度和核酸保存已成為關鍵的操作要點。液態生物檢體在特定應用情境中，例如突變檢測、微量殘存疾病研究、抗藥性監測和復發監測，正變得越來越重要，尤其是在組織獲取受限或重複取樣在臨床上困難的情況下。監管審查、品質認證和證據要求迫使檢查室實施檢驗的檢測方法、標準化報告和可追溯的工作流程。醫療系統也在強調多學科腫瘤學會議、數位病理學的應用、互通性和分散式檢體採集模式。這些變化正在將癌症切片檢查從單純的程序性服務轉變為數據密集的診斷平台，從而支持個人化醫療的發展。

人工智慧對癌症切片檢查的累積影響

人工智慧 (AI) 透過改善規劃、取樣、病理觀察解讀、工作流程效率和數據整合，對整個癌症切片檢查流程產生累積影響。在放射學領域，AI 驅動的影像分析可以輔助病灶檢測、分割、切片檢查路徑規劃和可疑觀察的優先排序，但醫生的監督和檢驗仍然至關重要。在病理學領域，計算工具正被評估和應用，以輔助腫瘤檢測、惡性腫瘤分類、有絲分裂計數估計、免疫組化定量、生物標記評分和數位切片分流。 AI 還可以幫助在工作流程早期識別不充分或低品質的樣本，從而減少重複檢測並加快後續分子檢測。在分子診斷領域，機器學習正被用於突變解讀、ctDNA 訊號分析、檢測品管以及將基因組檢測結果與臨床背景結合。 AI 在癌症切片檢查中的實際價值取決於精心選擇的資料集、具有臨床代表性的訓練隊列、可解釋性、網路安全、法規遵循和持續的性能監測。隨著部署的成熟，人工智慧有望不再取代專家，而是作為一種“增強層”，提高一致性、速度和診斷信心。

全球癌症切片檢查中人工智慧應用的關鍵區域性見解

在亞太地區，隨著中國、印度、日本、韓國和澳洲不斷擴大腫瘤基礎設施、分子診斷和數位健康計畫的覆蓋範圍，癌症切片檢查能力正在迅速提升。該地區面臨著沉重的癌症負擔和醫療資源分配的巨大差異，因此，經濟高效的組織切片檢查、液態生物檢體和集中式檢查室模式對於都市區和醫療資源匱乏地區的居民至關重要。在歐洲，協調一致的癌症控制計劃、以品質為中心的檢查室網路以及分子腫瘤委員會的日益普及正在取得成效，其重點在於統一檢測標準、數據保護以及成員國和非成員國之間公平的醫療資源獲取。北美地區的特點是積極採用精準腫瘤學、建立完善的病理學認證系統、廣泛應用影像引導的子程序以及在主要腫瘤類型中廣泛整合生物標記檢測。在拉丁美洲，儘管公共和私人部門對病理學現代化的投資正在增強癌症診斷能力，但保險報銷差異、檢體運輸和專家資源短缺等挑戰仍然存在。在非洲，病理人員、切片檢查獲取、檢體運輸和分子檢測等方面仍然存在局限性，但區域癌症控制策略、遠端病理診斷試點計畫和國際培訓合作正在推動診斷能力的逐步提升。在中東，尤其是在高所得的海灣國家，對三級癌症中心、基因組醫學舉措和醫療旅遊基礎設施的投資正在穩步推進，但資源匱乏地區仍然存在醫療資源取得方面的差距。

癌症切片檢查發展的關鍵群體分析

北約成員國與北美和歐洲的診斷系統有顯著的重疊，國防相關醫療網路、民用醫療基礎設施和跨境標準有助於提高癌症診斷的韌性、互通性和創新性。七國集團（G7）國家通常擁有成熟的切片檢查系統，並由專業人員、保險報銷機制、先進的影像技術、基因組檢測和積極的臨床研究提供支援。金磚國家（BRICS）的切片檢查領域呈現出多元化但又極具影響力的模式。中國和印度正在擴大大規模診斷能力，巴西和南非致力於改善公共部門的醫療服務和病理覆蓋範圍，俄羅斯在維持現有專業癌症醫療網路的同時，也正在擴大分子檢測活動。歐盟（EU）正透過監管協調、跨境研究、分子診斷標準以及支持早期檢測和個人化醫療的癌症控制舉措，推動癌症切片檢查品質的提升。在東南亞國協，由於癌症發生率上升、都市區醫院擴建以及國家篩檢計畫推動的切片檢查服務需求增加，擴充性的癌症診斷流程成為當務之急。然而，新加坡、馬來西亞、泰國、印尼、越南和菲律賓等國的醫療服務可近性差異顯著。海灣合作理事會（GCC）國家的醫療衛生系統正大力投資於先進的腫瘤中心、基因組檢測和數位病理基礎設施，這主要得益於國家醫療衛生轉型計劃以及對專科三級醫療機構的高度依賴。

影響主要國家癌症切片檢查實踐的趨勢

中國正透過擴建醫院、自主研發檢測方法以及建立大規模腫瘤中心，迅速提升其癌症切片檢查和基因組檢測能力。美國在生物標記主導的癌症切片檢查流程的廣泛臨床應用方面處於領先地位，這得益於其先進的腫瘤網路、認證實驗室、影像引導切片檢查的普及以及將切片檢查和液態生物檢體整合到治療主導過程中。日本的特點是病理學品質高、影像引導切片檢查技術先進，並積極採用伴隨診斷。印度正透過擴建三級癌症診療機構、私人診斷實驗室和分子病理學來提高切片檢查的可及性，但成本效益和遍遠地區的可及性仍然是主要挑戰。德國在病理學和臨床檢驗醫學方面擁有雄厚的基礎、高水準的診療流程以及豐富的分子診斷經驗。英國受益於全國性的癌症治療路徑、集中化的基因組檢測網路以及成熟的多學科團隊模式。澳洲透過整合有組織的癌症診療、健全的病理管治和區域遠端醫療模式，為大都會圈提供醫療服務。法國透過國家癌症戰略、分子檢測平台和結構化的醫療網路，支持精準腫瘤學的發展。韓國的特點是擁有先進的醫院基礎設施、採用先進技術、進行全國性的篩檢活動，並將分子診斷高度整合到腫瘤診療中。義大利和西班牙擁有完善的醫院切片檢查服務、活躍的腫瘤研究群體，並在數位病理學和分子檢測的應用方面取得了進展。加拿大強調公共資助的癌症診療、省級檢測途徑和以品質為導向的病理服務，但地理分散可能會阻礙偏遠地區及時獲得醫療服務。俄羅斯在重點地區設有專門的癌症醫療機構和切片檢查系統，並持續致力於分子診斷的現代化。巴西在主要城市和主要大學醫院擁有完善的癌症診療體系，但無論在哪個地區，在公共醫療機構的可近性和檢測結果的及時性方面仍然存在挑戰。墨西哥正透過公立和私立醫療機構擴大其癌症診斷能力，主要都市區獲得影像引導切片檢查和分子檢測的機會也在不斷改善。

為癌症切片檢查行業領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗、工作流程相容的癌症切片檢查解決方案，這些方案應在不增加操作複雜性的前提下，提高診斷品管、檢體適用性和縮短樣本返回時間。策略重點包括加強與癌症中心、放射科、病理檢查室和分子診斷提供者的夥伴關係，以建立端到端的切片檢查流程。各機構應投資於檢體品質控制、標準化的預分析方案、數位化病理學準備、人工智慧管治框架以及整合影像、病理、基因組學和電子健康記錄的互通資料系統。對於液態生物檢體和分子檢測，行業領導者必須提供同行評審的臨床證據、明確的預期用途以及符合監管要求的聲明。在准入策略方面，成本效益、報銷文件、人才培養以及解決分散的檢體至關重要，尤其是在新興的醫療保健系統中。為建立長期可靠性，行業相關人員應支持臨床醫生教育、能力驗證、外部品質評估、真實世界數據 (RWE) 的產生以及透明的報告標準。競爭優勢源自於提供可靠、微創且數據驅動的癌症診斷，這些診斷能夠融入現有的癌症治療流程，並支持精準的治療決策。

基於切片檢查的癌症活體組織切片調查方法

本執行摘要採用結構化的二級研究方法編寫，重點關注檢驗且有數據支持的資訊來源，包括公共衛生機構、癌症登記處、臨床指南制定機構、同行評審的醫學文獻、監管研究途徑、病理學認證標準以及腫瘤政策出版物。調查方法強調對流行病學、診斷實踐、技術應用、臨床工作流程和當地醫療基礎設施等方面的檢驗進行三角驗證。研究結果評估其與癌症切片檢查技術、組織和液態生物檢體應用、分子切片檢查、人工智慧、數位病理學和精準腫瘤學的相關性。定性整合用於識別轉型主題、區域差異、臨床應用促進因素、准入障礙和營運重點。本分析有意排除市場規模估算、市場規模計算、市場佔有率和預測。所有研究結果均以支持經營團隊決策的方式呈現，同時與實證醫學、監管要求和實際醫療服務保持一致。

結論：癌症切片檢查是個人化癌症治療的基礎

切片檢查正逐漸發展成為精準腫瘤學的核心平台，將程序性診斷與病理學、基因組學、影像學、人工智慧和時間序列治療監測相結合。在醫療系統能夠整合微創取樣、高品質組織處理、檢驗的分子檢測、數位病理學以及多學科觀察的領域，湧現出最大的機會。區域和國家間的差異仍然顯著，尤其是在獲得專業病理診斷、分子檢測、保險報銷和檢體物流方面。然而，全球趨勢清晰可見：癌症治療越來越依賴準確、及時且數據豐富的切片檢查結果。專注於臨床檢驗、工作流程整合、品質保證、公平取得以及負責任的人工智慧實施的機構，將更有能力支持下一代癌症診斷和個人化醫療的發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：癌症切片檢查市場：依切片檢查類型分類

  • 手術切片檢查
    • 切片檢查
    • 切除切片檢查
  • 針刺切片
    • 細針穿刺切片檢查
    • 核心針穿刺切片
  • 液態生物檢體
    • 循環性腫瘤細胞
    • 細胞中的遊離DNA
    • 外泌體
  • 骨髓切片檢查
  • 皮膚切片檢查
    • 沖床
    • 刮取切片檢查

第8章：癌症切片檢查市場：依癌症類型分類

  • 乳癌
  • 肺癌
  • 攝護腺癌
  • 結腸癌
  • 血癌
  • 肝癌
  • 腎癌

第9章：癌症切片檢查市場：依技術分類

  • 影像引導切片檢查
  • 徒手切片檢查
  • 機器人輔助切片檢查

第10章 癌症切片檢查市場：依樣本類型分類

  • 組織切片檢查樣本
  • 液態生物檢體樣本
    • 電漿
    • 血清
    • 尿

第11章：癌症切片檢查市場：按應用領域分類

  • 診斷
  • 預後
  • 治療方案
  • 疾病監測
  • 復發檢測

第12章 癌症切片檢查市場：依最終用戶分類

  • 門診手術中心
  • 診斷影像中心
  • 醫院
    • 私人的
    • 民眾
  • 診所

第13章：癌症切片檢查市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：癌症切片檢查市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 癌症切片檢查市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Agilent Technologies, Inc.
  • Amoy Diagnostics Co., Ltd.
  • ANGLE plc
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix, Inc.
  • Caris Life Sciences, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • MDxHealth SA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • Personal Genome Diagnostics Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.
Product Code: MRR-C27187914300

The Cancer Biopsy Market is projected to grow by USD 61.35 billion at a CAGR of 8.44% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.77 billion
Estimated Year [2026] USD 37.63 billion
Forecast Year [2032] USD 61.35 billion
CAGR (%) 8.44%

Cancer biopsy remains a cornerstone of oncology diagnosis, staging, treatment selection, and disease monitoring. The field spans tissue biopsy, fine-needle aspiration, core needle biopsy, surgical biopsy, image-guided biopsy, liquid biopsy, circulating tumor DNA testing, and molecular pathology workflows. Demand is being shaped by the global cancer burden, earlier screening initiatives, and the expansion of precision oncology, where biomarker-driven therapy decisions increasingly depend on reliable tumor sampling and genomic characterization. Verified clinical practice patterns show that biopsy results guide tumor classification, receptor testing, mutation profiling, immunohistochemistry, next-generation sequencing, and eligibility assessment for targeted therapies and immunotherapies. At the same time, clinicians are prioritizing minimally invasive procedures, faster turnaround times, sample adequacy, patient safety, and integration between pathology, radiology, oncology, and laboratory information systems. The executive outlook for cancer biopsy is therefore defined by a shift from diagnosis alone toward a continuous, evidence-based cancer management model that connects tissue morphology, molecular data, imaging, and longitudinal monitoring.

Transformative Shifts Reshaping the Cancer Biopsy Landscape

The cancer biopsy landscape is undergoing structural transformation as oncology moves from single-point diagnosis to dynamic disease profiling. Image-guided biopsy is improving lesion targeting in lung, breast, liver, prostate, and deep-tissue tumors, while endoscopic and robotic-assisted approaches are expanding access to anatomically complex sites. Molecular testing is also changing specimen requirements, making pre-analytical quality, fixation protocols, tumor cellularity, and nucleic acid preservation critical operational priorities. Liquid biopsy is gaining clinical relevance for selected use cases such as mutation detection, minimal residual disease research, resistance monitoring, and recurrence surveillance, particularly when tissue access is limited or repeat sampling is clinically challenging. Regulatory scrutiny, quality accreditation, and evidence requirements are pushing laboratories toward validated assays, standardized reporting, and traceable workflows. Healthcare systems are also emphasizing multidisciplinary tumor boards, digital pathology adoption, interoperability, and decentralized sample collection models. These shifts are elevating cancer biopsy from a procedural service into a data-intensive diagnostic platform that supports personalized treatment pathways.

Cumulative Impact of Artificial Intelligence on Cancer Biopsy

Artificial intelligence is creating cumulative impact across the cancer biopsy continuum by improving planning, sampling, pathology interpretation, workflow efficiency, and data integration. In radiology, AI-enabled image analysis can support lesion detection, segmentation, biopsy route planning, and prioritization of suspicious findings, although physician oversight and validation remain essential. In pathology, computational tools are being evaluated and deployed to assist with tumor detection, grading support, mitotic count estimation, immunohistochemistry quantification, biomarker scoring, and digital slide triage. AI can also help identify insufficient or low-quality samples earlier in the workflow, reducing repeat procedures and accelerating downstream molecular testing. In molecular diagnostics, machine learning is being applied to variant interpretation, ctDNA signal analysis, assay quality control, and integration of genomic results with clinical context. The practical value of AI in cancer biopsy depends on curated datasets, clinically representative training cohorts, explainability, cybersecurity, regulatory compliance, and continuous performance monitoring. As adoption matures, AI is expected to function less as a replacement for specialists and more as an augmentation layer that strengthens consistency, speed, and diagnostic confidence.

Key Regional Insights Across Global Cancer Biopsy Adoption

Asia-Pacific is experiencing rapid advancement in cancer biopsy capabilities as China, India, Japan, South Korea, and Australia expand oncology infrastructure, molecular diagnostics access, and digital health programs. The region faces a substantial cancer burden and wide variability in healthcare access, making cost-efficient tissue biopsy, liquid biopsy, and centralized laboratory models important for both urban and underserved populations. Europe benefits from coordinated cancer plans, quality-driven laboratory networks, and growing use of molecular tumor boards, with emphasis on harmonized testing standards, data protection, and equitable access across member and non-member countries. North America is characterized by strong adoption of precision oncology, established pathology accreditation practices, extensive use of image-guided procedures, and broad clinical integration of biomarker testing across major tumor types. Latin America is strengthening cancer diagnosis capacity through public and private investments in pathology modernization, though uneven reimbursement, specimen logistics, and specialist availability remain persistent challenges. Africa continues to face constraints in pathology workforce, biopsy access, sample transport, and molecular testing availability, but regional cancer control strategies, telepathology pilots, and international training collaborations are supporting incremental improvements in diagnostic capacity. The Middle East is investing in tertiary oncology centers, genomic medicine initiatives, and medical tourism infrastructure, particularly in high-income Gulf economies, while access gaps remain across lower-resource settings.

Key Group Insights for Cancer Biopsy Development

NATO countries overlap significantly with North American and European diagnostic systems, where defense-related medical networks, civilian healthcare infrastructure, and cross-border standards contribute to resilience, interoperability, and innovation in cancer diagnostics. G7 countries generally demonstrate mature biopsy ecosystems supported by specialist workforces, reimbursement structures, advanced imaging, genomic testing, and strong clinical research activity. BRICS economies represent diverse but influential cancer biopsy environments: China and India are expanding high-volume diagnostic capacity, Brazil and South Africa are working to improve public-sector access and pathology coverage, and Russia maintains established specialist oncology networks with increasing molecular testing activity. The European Union is advancing cancer biopsy quality through regulatory harmonization, cross-border research, molecular diagnostics standards, and cancer mission initiatives that support earlier detection and personalized medicine. ASEAN countries are prioritizing scalable cancer diagnostic pathways as rising cancer incidence, urban hospital expansion, and national screening programs increase demand for biopsy services, although access differs markedly between Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. GCC health systems are investing in advanced oncology centers, genomic testing, and digital pathology infrastructure, supported by national health transformation agendas and a high dependence on specialized tertiary care.

Key Country Insights Shaping Cancer Biopsy Practices

China is rapidly scaling cancer biopsy and genomic testing capacity through hospital expansion, domestic assay development, and large oncology centers. The United States leads in broad clinical use of biomarker-driven cancer biopsy workflows, supported by advanced oncology networks, accredited laboratories, image-guided biopsy availability, and integration of tissue and liquid biopsy into treatment decision-making. Japan demonstrates high-quality pathology standards, advanced imaging-guided biopsy practices, and strong adoption of companion diagnostics. India is advancing biopsy access through tertiary cancer institutes, private diagnostics, and expanding molecular pathology, while affordability and rural access remain central challenges. Germany has a strong pathology and laboratory medicine base, high procedural quality, and extensive molecular diagnostics expertise. The United Kingdom benefits from national cancer pathways, centralized genomic laboratory networks, and established multidisciplinary team models. Australia combines organized cancer care, strong pathology governance, and regional telehealth models to support access beyond metropolitan centers. France supports precision oncology through national cancer strategies, molecular testing platforms, and structured care networks. South Korea is distinguished by advanced hospital infrastructure, high technology adoption, national screening activity, and strong integration of molecular diagnostics into oncology care. Italy and Spain have well-developed hospital-based biopsy services, active oncology research communities, and growing digital pathology and molecular testing adoption. Canada emphasizes publicly funded cancer care, provincial testing pathways, and quality-focused pathology services, while geographic dispersion can affect timely access in remote communities. Russia maintains specialized oncology institutions and biopsy capability across major regions, with ongoing emphasis on modernizing molecular diagnostics. Brazil has significant cancer care capacity in large cities and leading academic hospitals, though public-sector access and turnaround time challenges persist across regions. Mexico is expanding oncology diagnostics through public institutions and private providers, with improving access to image-guided biopsy and molecular testing in major urban centers.

Actionable Recommendations for Cancer Biopsy Industry Leaders

Industry leaders should prioritize clinically validated, workflow-compatible cancer biopsy solutions that improve diagnostic accuracy, sample adequacy, and turnaround time without increasing procedural complexity. Strategic focus should include strengthening partnerships with oncology centers, radiology departments, pathology laboratories, and molecular diagnostic providers to create end-to-end biopsy pathways. Organizations should invest in specimen quality controls, standardized pre-analytical protocols, digital pathology readiness, AI governance frameworks, and interoperable data systems that connect imaging, pathology, genomics, and electronic health records. For liquid biopsy and molecular testing, leaders should align claims with peer-reviewed clinical evidence, clear intended use, and regulatory expectations. Access strategies must address affordability, reimbursement documentation, workforce training, and decentralized sample logistics, especially in emerging health systems. To build long-term credibility, industry participants should support clinician education, proficiency testing, external quality assessment, real-world evidence generation, and transparent reporting standards. Competitive advantage will come from enabling reliable, minimally invasive, data-rich cancer diagnosis that fits existing oncology workflows and supports precision treatment decisions.

Research Methodology for Evidence-Based Cancer Biopsy Insights

This executive summary is developed using a structured secondary research approach focused on verified, data-backed sources, including public health agencies, cancer registries, clinical guideline bodies, peer-reviewed medical literature, regulatory documents, pathology accreditation standards, and oncology policy publications. The methodology emphasizes triangulation of evidence across epidemiology, diagnostic practice, technology adoption, clinical workflow, and regional healthcare infrastructure. Insights are assessed for relevance to cancer biopsy procedures, tissue and liquid biopsy applications, molecular diagnostics, artificial intelligence, digital pathology, and precision oncology. Qualitative synthesis is used to identify transformation themes, regional variations, clinical adoption drivers, access barriers, and operational priorities. The analysis intentionally excludes market estimation, market sizing, market share, and forecasting. All findings are framed to support executive decision-making while maintaining alignment with evidence-based medicine, regulatory expectations, and real-world healthcare delivery conditions.

Conclusion: Cancer Biopsy as a Foundation of Personalized Cancer Care

Cancer biopsy is evolving into a central platform for precision oncology, linking procedural diagnostics with pathology, genomics, imaging, artificial intelligence, and longitudinal treatment monitoring. The strongest opportunities are emerging where healthcare systems can combine minimally invasive sampling, high-quality tissue handling, validated molecular assays, digital pathology, and multidisciplinary interpretation. Regional and country-level differences remain significant, especially in access to specialist pathology, molecular testing, reimbursement, and sample logistics. However, global momentum is clear: cancer care increasingly depends on accurate, timely, and data-rich biopsy results. Organizations that focus on clinical validation, workflow integration, quality assurance, equitable access, and responsible AI adoption will be best positioned to support the next generation of cancer diagnosis and personalized treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Biopsy Market, by Biopsy Type

  • 7.1. Introduction
  • 7.2. Surgical Biopsy
    • 7.2.1. Incisional
    • 7.2.2. Excisional
  • 7.3. Needle Biopsy
    • 7.3.1. Fine Needle Aspiration Biopsy
    • 7.3.2. Core Needle Biopsy
  • 7.4. Liquid Biopsy
    • 7.4.1. Circulating Tumor Cells
    • 7.4.2. Cell Free DNA
    • 7.4.3. Exosomes
  • 7.5. Bone Marrow Biopsy
  • 7.6. Skin Biopsy
    • 7.6.1. Punch
    • 7.6.2. Shave

8. Cancer Biopsy Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Lung Cancer
  • 8.4. Prostate Cancer
  • 8.5. Colorectal Cancer
  • 8.6. Blood Cancer
  • 8.7. Liver Cancer
  • 8.8. Kidney Cancer

9. Cancer Biopsy Market, by Technology

  • 9.1. Introduction
  • 9.2. Imaging Guided Biopsy
  • 9.3. Manual Freehand Biopsy
  • 9.4. Robotic Assisted Biopsy

10. Cancer Biopsy Market, by Sample Type

  • 10.1. Introduction
  • 10.2. Tissue Biopsy Samples
  • 10.3. Liquid Biopsy Samples
    • 10.3.1. Blood Plasma
    • 10.3.2. Serum
    • 10.3.3. Urine

11. Cancer Biopsy Market, by Application

  • 11.1. Introduction
  • 11.2. Diagnosis
  • 11.3. Prognosis
  • 11.4. Treatment Selection
  • 11.5. Disease Monitoring
  • 11.6. Recurrence Detection

12. Cancer Biopsy Market, by End User

  • 12.1. Introduction
  • 12.2. Ambulatory Surgical Centers
  • 12.3. Diagnostic Imaging Centers
  • 12.4. Hospitals
    • 12.4.1. Private
    • 12.4.2. Public
  • 12.5. Physicians Offices

13. Cancer Biopsy Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Cancer Biopsy Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Cancer Biopsy Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Agilent Technologies, Inc.
  • 17.2. Amoy Diagnostics Co., Ltd.
  • 17.3. ANGLE plc
  • 17.4. Becton, Dickinson and Company
  • 17.5. Bio-Rad Laboratories, Inc.
  • 17.6. Biocept, Inc.
  • 17.7. Biodesix, Inc.
  • 17.8. Caris Life Sciences, Inc.
  • 17.9. Danaher Corporation
  • 17.10. Exact Sciences Corporation
  • 17.11. F. Hoffmann-La Roche Ltd.
  • 17.12. GRAIL, Inc.
  • 17.13. Guardant Health, Inc.
  • 17.14. Hologic, Inc.
  • 17.15. Illumina, Inc.
  • 17.16. Laboratory Corporation of America Holdings
  • 17.17. Lucence Health Inc.
  • 17.18. MDxHealth SA
  • 17.19. Myriad Genetics, Inc.
  • 17.20. Natera, Inc.
  • 17.21. NeoGenomics Laboratories, Inc.
  • 17.22. Personal Genome Diagnostics Inc.
  • 17.23. QIAGEN N.V.
  • 17.24. Quest Diagnostics Incorporated
  • 17.25. Siemens Healthineers AG
  • 17.26. Sysmex Corporation
  • 17.27. Thermo Fisher Scientific Inc.
  • 17.28. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOPSY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER BIOPSY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER BIOPSY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER BIOPSY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SURGICAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SURGICAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SURGICAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INCISIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INCISIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INCISIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EXCISIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EXCISIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EXCISIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEEDLE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEEDLE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEEDLE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FINE NEEDLE ASPIRATION BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FINE NEEDLE ASPIRATION BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FINE NEEDLE ASPIRATION BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL FREE DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL FREE DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL FREE DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EXOSOMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EXOSOMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EXOSOMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BONE MARROW BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BONE MARROW BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BONE MARROW BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SKIN BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SKIN BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SKIN BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PUNCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PUNCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PUNCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHAVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SHAVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHAVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL KIDNEY CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL KIDNEY CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL KIDNEY CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMAGING GUIDED BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMAGING GUIDED BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMAGING GUIDED BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MANUAL FREEHAND BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MANUAL FREEHAND BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MANUAL FREEHAND BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ROBOTIC ASSISTED BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ROBOTIC ASSISTED BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ROBOTIC ASSISTED BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TISSUE BIOPSY SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TISSUE BIOPSY SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TISSUE BIOPSY SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LIQUID BIOPSY SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIQUID BIOPSY SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LIQUID BIOPSY SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TREATMENT SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TREATMENT SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TREATMENT SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DISEASE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DISEASE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DISEASE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RECURRENCE DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RECURRENCE DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RECURRENCE DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DIAGNOSTIC IMAGING CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIAGNOSTIC IMAGING CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIAGNOSTIC IMAGING CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PRIVATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PRIVATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PRIVATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PUBLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PUBLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PUBLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PHYSICIANS OFFICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PHYSICIANS OFFICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PHYSICIANS OFFICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. NATO CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. NATO CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. G7 CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 226. G7 CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. GCC CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 277. GCC CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 278. GCC CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 279. GCC CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. GCC CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 284. GCC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. GCC CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. GCC CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 287. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. JAPAN CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 317. JAPAN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 318. JAPAN CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 319. JAPAN CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 320. JAPAN CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. JAPAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. JAPAN CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. INDIA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 331. INDIA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 332. INDIA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 333. INDIA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. INDIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. INDIA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. INDIA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 337. INDIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 338. INDIA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 339. INDIA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. GERMANY CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 343. GERMANY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 344. GERMANY CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 345. GERMANY CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 346. GERMANY CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. GERMANY CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 348. GERMANY CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. GERMANY CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 350. GERMANY CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 351. GERMANY CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 352. GERMANY CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 356. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 358. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 359. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 360. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 361. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 362. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 363. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 364. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 365. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 366. AUSTRALIA CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 367. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 368. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 369. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 370. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 371. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 372. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 373. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 374. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 375. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 376. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 377. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 378. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 379. FRANCE CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 380. FRANCE CANCER BIOPSY MARKET SIZE, BY BIOPSY TYPE, 2018-2032 (USD MILLION)
  • TABLE 381. FRANCE CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 382. FRANCE CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 383. FRANCE CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 384. FRANCE CANCER BIOPSY MARKET SIZE, BY SKIN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 385. FRANCE CANCER BIOPSY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 386. FRANCE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)